Clinical-genomic nomogram for predicting sensitivity to second-line immunotherapy for advanced non-small cell lung cancer
Based on real-world clinical settings, the clinical genomic nomogram, which involved limited input variables that were economical and easy to obtain, demonstrated a good ability to predict the response to second-line ICI treatment in advanced NSCLC.
Authors
- Apostolos C. Agrafiotis (ORCID: https://orcid.org/0000-0002-7525-2080)
- Peng Zhang (ORCID: https://orcid.org/0000-0002-9092-9563)
- Ai Wang (ORCID: https://orcid.org/0000-0002-3030-1539)
- Chao Xie (ORCID: https://orcid.org/0000-0001-7645-1922)
- Baosheng Li (ORCID: https://orcid.org/0000-0002-3225-5740)
- Ying Hua (ORCID: https://orcid.org/0000-0002-0652-2956)
Institutions
- Université Libre de Bruxelles (BE)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shandong Tumor Hospital (CN)
- Centre Hospitalier Universitaire de Saint-Pierre (BE)
- Shandong First Medical University (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/tlcr-2024-1249
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00